乾癬治療薬市場：治療クラス別、治療タイプ別、作用機序別、投与経路別、流通チャネル別、用途別-2025-2030年の世界予測

乾癬治療薬市場は、2023年に96億7,000万米ドルと評価され、2024年には108億3,000万米ドルに達すると予測され、CAGR 12.07％で成長し、2030年には214億8,000万米ドルに達すると予測されています。

乾癬治療薬の対象範囲には、鱗屑と炎症につながる皮膚細胞の急速な増殖を特徴とする慢性的な自己免疫疾患である乾癬に関連する症状の管理と緩和を目的とした一連の治療が含まれます。数百万人が罹患し、生活の質に大きな影響を与える乾癬の世界の有病率の増加により、これらの薬剤の必要性が強調されています。治療は生物学的製剤、経口全身治療薬、局所治療薬など様々なタイプに及び、それぞれ乾癬の重症度やタイプに合わせて調整されます。最終的な使用範囲は主に病院、診療所、在宅医療の場であり、生物学的製剤はその複雑性から臨床の場で投与されることが多いです。

乾癬治療薬市場に影響を与える主な成長要因としては、標的治療につながるバイオテクノロジー研究の進展、ヘルスケア支出の増加、乾癬とその治療選択肢に対する意識の高まりなどが挙げられます。さらに、様々な臨床試験段階にある薬剤のパイプラインが拡大していることも、大きな成長機会をもたらしています。特に、患者中心の治療へのシフトと個別化医療の需要が市場の可能性を押し上げ、都市化とライフスタイルの変化による新興諸国での乾癬罹患率の上昇も同様です。

しかし、いくつかの課題も存在します。生物学的製剤による治療に伴う高額な費用と、医薬品承認に関する厳しい規制要件が大きな障壁となっています。さらに、低所得地域では医薬品へのアクセスが制限されることがあり、市場浸透に影響を与えています。

革新的な取り組みとしては、費用対効果の高いバイオシミラーの開発、既存薬の効能改善、患者のコンプライアンスを高めるための新規デリバリーシステムの探求などが考えられます。症状モニタリング用のウェアラブルデバイスなど、デジタルヘルスの統合には十分な機会があり、より良い管理を促進することができます。市場は、急速な技術進歩や、より全体的で患者に優しい治療アプローチへのダイナミックなシフトを特徴としています。このような技術革新を活用し、コスト面でのアクセシビリティの障壁に対処する企業は、大幅な成長を促進し、この進化する市場環境で競争力を維持できる可能性があります。

市場力学：急速に進化する乾癬治療薬市場の主要市場インサイトを公開

乾癬治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 乾癬の有病率の増加
  • 老人人口の増加と尋常性乾癬および乾癬性関節炎の有病率の増加
  • 乾癬治療薬の承認プロセスの容易さ
• 市場抑制要因
  • 高い治療費
• 市場機会
  • 乾癬研究とパイプライン医薬品の増加
• 市場の課題
  • 薬の副作用

ポーターの5つの力乾癬治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：乾癬治療薬市場における外部からの影響の把握

外部マクロ環境要因は、乾癬治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析乾癬治療薬市場における競合情勢の把握

乾癬治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス乾癬治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、乾癬治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨乾癬治療薬市場における成功への道筋を描く

乾癬治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 乾癬の罹患率増加
    • 高齢者人口の増加と、尋常性乾癬および乾癬性関節炎の罹患率の増加
    • 乾癬治療薬の承認プロセスの容易さ
  • 抑制要因
    • 治療費が高い
  • 機会
    • 乾癬調査とパイプライン薬の増加
  • 課題
    • 薬の副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 乾癬治療薬市場治療クラス別

• インターロイキン阻害剤
• 腫瘍壊死因子阻害剤

第7章 乾癬治療薬市場治療の種類別

• 生物学的製剤
• 低分子全身性薬剤
• 熱帯療法

第8章 乾癬治療薬市場作用機序別

• インターロイキン阻害剤
• PDE4阻害剤
• TNFアルファ阻害剤

第9章 乾癬治療薬市場：投与経路別

• オーラル
• 非経口
• 話題

第10章 乾癬治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 乾癬治療薬市場：用途別

• 関節炎
• 紅皮症
• 滴状
• 間擦性
• ネイル
• プラーク
• 膿疱性

第12章 南北アメリカの乾癬治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の乾癬治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの乾癬治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Celgene Corporation
• Dr.Reddy's Laboratories
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Leo Pharma AS
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Stiefel Laboratories Inc.
• Sun Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. PSORIASIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. PSORIASIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PSORIASIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PSORIASIS DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. CANADA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 54. CANADA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. CANADA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 56. CANADA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. CANADA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CANADA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. CHINA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 86. CHINA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. CHINA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 88. CHINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. CHINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. CHINA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. INDIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 92. INDIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. INDIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 94. INDIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. INDIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. INDIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. ITALY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 195. ITALY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 196. ITALY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 197. ITALY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. ITALY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. ITALY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. POLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 219. POLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 220. POLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 221. POLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. POLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. POLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. QATAR PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 225. QATAR PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 226. QATAR PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 227. QATAR PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. QATAR PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. QATAR PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 285. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Psoriasis Drugs Market was valued at USD 9.67 billion in 2023, expected to reach USD 10.83 billion in 2024, and is projected to grow at a CAGR of 12.07%, to USD 21.48 billion by 2030.

The scope of psoriasis drugs encompasses a range of treatments designed to manage and alleviate the symptoms associated with psoriasis, a chronic autoimmune condition characterized by the rapid growth of skin cells leading to scaling and inflammation. The necessity of these drugs is underscored by the increasing prevalence of psoriasis globally, which affects millions and can significantly impact quality of life. Applications extend across various drug types including biologics, oral systemic treatments, and topical therapies, each tailored to different severities and types of psoriasis. End-use scope primarily involves hospitals, clinics, and home care settings, with biologics frequently administered in clinical settings due to their complexity.

Key growth factors influencing the psoriasis drugs market include advancing research in biotechnology leading to targeted therapies, increased healthcare spending, and heightened awareness of psoriasis and its treatment options. Additionally, the expanding pipeline of drugs in various stages of clinical trials presents significant growth opportunities. Notably, the shift towards patient-centric care and the demand for personalized medicine boost the market's potential, as does the rising incidence of psoriasis in developing countries due to urbanization and changing lifestyles.

However, several challenges exist. High costs associated with biologic treatments and stringent regulatory requirements for drug approval pose significant barriers. Moreover, access to medications in low-income regions can be limited, affecting market penetration.

Innovation efforts could focus on developing cost-effective biosimilars, improving the efficacy of existing drugs, and exploring novel delivery systems to enhance patient compliance. There is ample opportunity in digital health integration, such as wearable devices for symptom monitoring, which can facilitate better management. The market is characterized by rapid technological advancements and dynamic shifts towards more holistic and patient-friendly treatment approaches. Companies that leverage these innovations and address the cost accessibility barriers can potentially drive substantial growth and maintain a competitive edge in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Psoriasis Drugs Market

The Psoriasis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of psoriasis
  • Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
  • Ease of process of approval of psoriasis drugs
• Market Restraints
  • High cost of treatment
• Market Opportunities
  • Increase in psoriasis research and pipeline drugs
• Market Challenges
  • Side effects of the medication

Porter's Five Forces: A Strategic Tool for Navigating the Psoriasis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Psoriasis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Psoriasis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Psoriasis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Psoriasis Drugs Market

A detailed market share analysis in the Psoriasis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Psoriasis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Psoriasis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Psoriasis Drugs Market

A strategic analysis of the Psoriasis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Psoriasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc., Celgene Corporation, Dr.Reddy's Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., Leo Pharma AS, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Ltd, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Psoriasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Class, market is studied across Interleukin Inhibitors and Tumor Necrosis Factor Inhibitor.
• Based on Type of Treatment, market is studied across Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies.
• Based on Mechanism of Action, market is studied across Interleukin Inhibitors, PDE4 Inhibitors, and TNF Alpha Inhibitors.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Application, market is studied across Arthritis, Erythrodermic, Guttate, Intertriginous, Nail, Plaque, and Pustular.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of psoriasis
    • 5.1.1.2. Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
    • 5.1.1.3. Ease of process of approval of psoriasis drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in psoriasis research and pipeline drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects of the medication
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Psoriasis Drugs Market, by Therapeutic Class

• 6.1. Introduction
• 6.2. Interleukin Inhibitors
• 6.3. Tumor Necrosis Factor Inhibitor

7. Psoriasis Drugs Market, by Type of Treatment

• 7.1. Introduction
• 7.2. Biologic Drugs
• 7.3. Small Molecule Systemic Drugs
• 7.4. Tropical Therapies

8. Psoriasis Drugs Market, by Mechanism of Action

• 8.1. Introduction
• 8.2. Interleukin Inhibitors
• 8.3. PDE4 Inhibitors
• 8.4. TNF Alpha Inhibitors

9. Psoriasis Drugs Market, by Route of Administration

• 9.1. Introduction
• 9.2. Oral
• 9.3. Parenteral
• 9.4. Topical

10. Psoriasis Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Psoriasis Drugs Market, by Application

• 11.1. Introduction
• 11.2. Arthritis
• 11.3. Erythrodermic
• 11.4. Guttate
• 11.5. Intertriginous
• 11.6. Nail
• 11.7. Plaque
• 11.8. Pustular

12. Americas Psoriasis Drugs Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Psoriasis Drugs Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Psoriasis Drugs Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. AstraZeneca Plc
• 4. Bausch Health Companies Inc.
• 5. Celgene Corporation
• 6. Dr.Reddy's Laboratories
• 7. Eli Lilly and Company
• 8. Johnson & Johnson Services, Inc.
• 9. Leo Pharma AS
• 10. Merck & Co., Inc.
• 11. Novartis International AG
• 12. Pfizer Inc.
• 13. Stiefel Laboratories Inc.
• 14. Sun Pharmaceutical Industries Ltd
• 15. Takeda Pharmaceutical Company Limited